The Drug Developments of Hydrogen Sulfide on Cardiovascular Disease.
Article Details
- CitationCopy to clipboard
Wen YD, Wang H, Zhu YZ
The Drug Developments of Hydrogen Sulfide on Cardiovascular Disease.
Oxid Med Cell Longev. 2018 Jul 29;2018:4010395. doi: 10.1155/2018/4010395. eCollection 2018.
- PubMed ID
- 30151069 [ View in PubMed]
- Abstract
The recognition of hydrogen sulfide (H2S) has been evolved from a toxic gas to a physiological mediator, exhibiting properties similar to NO and CO. On the one hand, H2S is produced from L-cysteine by enzymes of cystathionine gamma-lyase (CSE) and cystathionine beta-synthase (CBS), 3-mercaptopyruvate sulfurtransferase (3MST) in combination with aspartate aminotransferase (AAT) (also called as cysteine aminotransferase, CAT); on the other hand, H2S is produced from D-cysteine by enzymes of D-amino acid oxidase (DAO). Besides sulfide salt, several sulfide-releasing compounds have been synthesized, including organosulfur compounds, Lawesson's reagent and analogs, and plant-derived natural products. Based on garlic extractions, we synthesized S-propargyl-L-cysteine (SPRC) and its analogs to contribute our endeavors on drug development of sulfide-containing compounds. A multitude of evidences has presented H2S is widely involved in the roles of physiological and pathological process, including hypertension, atherosclerosis, angiogenesis, and myocardial infarcts. This review summarizes current sulfide compounds, available H2S measurements, and potential molecular mechanisms involved in cardioprotections to help researchers develop further applications and therapeutically drugs.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Cysteine Aspartate aminotransferase, cytoplasmic Protein Humans UnknownSubstrateDetails Cysteine Aspartate aminotransferase, mitochondrial Protein Humans UnknownSubstrateDetails